Schering-Plough Corporation today reported that a jury in the United States District Court for the district of New Jersey has decided to award Boehringer- Ingelheim $6.905 million plus interest, based on a prior decision finding infringement of a Boehringer-Ingelheim swine vaccine patent in 2000.

In January 2000, a jury found that the Company's PRIME PAC PRRS (Porcine Respiratory and Reproductive Syndrome) vaccine infringed a patent owned by Boehringer-Ingelheim Vetmedica, Inc. This vaccine was used to prevent PRRS in swine. An injunction was issued in August 2000 barring further sales of the Company's vaccine. The Company appealed, and the verdict was affirmed by the appellate court in February 2003.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world.